Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
PRECIGEN INC (PGEN) Stock Price & Overview
NASDAQ:PGEN • US74017N1054
Current stock price
4.08 USD
-0.08 (-1.92%)
At close:
4.07 USD
-0.01 (-0.25%)
After Hours:
The current stock price of PGEN is 4.08 USD. Today PGEN is down by -1.92%. In the past month the price increased by 3.55%. In the past year, price increased by 159.87%.
PGEN Key Statistics
52-Week Range1.225 - 5.465
Current PGEN stock price positioned within its 52-week range.
1-Month Range3.8 - 4.37
Current PGEN stock price positioned within its 1-month range.
- Market Cap
- 1.444B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.29
- Dividend Yield
- N/A
PGEN Stock Performance
Today
-1.92%
1 Week
-1.21%
1 Month
+3.55%
3 Months
-9.13%
Longer-term
6 Months -1.45%
1 Year +159.87%
2 Years +191.43%
3 Years +242.86%
5 Years -38.18%
10 Years N/A
PGEN Stock Chart
PGEN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PGEN. When comparing the yearly performance of all stocks, PGEN is one of the better performing stocks in the market, outperforming 93.76% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
PGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PGEN. Both the profitability and financial health of PGEN have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PGEN Earnings
On March 25, 2026 PGEN reported an EPS of -0.07 and a revenue of 4.57M. The company beat EPS expectations (17.64% surprise) and missed revenue expectations (-45.98% surprise).
Next Earnings DateMay 11, 2026
Last Earnings DateMar 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.07
Revenue Reported4.565M
EPS Surprise 17.64%
Revenue Surprise -45.98%
PGEN Forecast & Estimates
9 analysts have analysed PGEN and the average price target is 9.69 USD. This implies a price increase of 137.5% is expected in the next year compared to the current price of 4.08.
For the next year, analysts expect an EPS growth of 96.31% and a revenue growth 577.54% for PGEN
Analysts
Analysts80
Price Target9.69 (137.5%)
EPS Next Y96.31%
Revenue Next Year577.54%
PGEN Index Membership
PGEN is currently included in the following stock indexes tracked on ChartMill.
PGEN Financial Highlights
Over the last trailing twelve months PGEN reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS decreased by -268.57% compared to the year before.
Income Statements
Revenue(TTM)9.68M
Net Income(TTM)-429.64M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -276.29% | ||
| ROE | -2054.62% | ||
| Debt/Equity | 4.46 |
Chartmill High Growth Momentum
EPS Q2Q%-16.67%
Sales Q2Q%283.61%
EPS 1Y (TTM)-268.57%
Revenue 1Y (TTM)146.73%
PGEN Ownership
Ownership
Inst Owners73.14%
Shares353.93M
Float304.61M
Ins Owners2.98%
Short Float %13.06%
Short Ratio8.21
PGEN Industry Overview
PGEN operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.8%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.1
PGEN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PGEN
Company Profile
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 143 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Company Info
IPO: 2013-08-08
PRECIGEN INC
20374 Seneca Meadows Parkway
Germantown MARYLAND 20876 US
CEO: Helen Sabzevari
Employees: 160
Phone: 13015569900
PRECIGEN INC / PGEN FAQ
What does PGEN do?
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 143 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Can you provide the latest stock price for PRECIGEN INC?
The current stock price of PGEN is 4.08 USD. The price decreased by -1.92% in the last trading session.
Does PRECIGEN INC pay dividends?
PGEN does not pay a dividend.
How is the ChartMill rating for PRECIGEN INC?
PGEN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for PGEN stock?
The Revenue of PRECIGEN INC (PGEN) is expected to grow by 577.54% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for PRECIGEN INC?
PRECIGEN INC (PGEN) currently has 160 employees.
What is the market capitalization of PGEN stock?
PRECIGEN INC (PGEN) has a market capitalization of 1.44B USD. This makes PGEN a Small Cap stock.